Last reviewed · How we verify
Loteprednol etabonate 0.2%
Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Loteprednol etabonate is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Seasonal allergic conjunctivitis, Uveitis.
At a glance
| Generic name | Loteprednol etabonate 0.2% |
|---|---|
| Also known as | Alrex, Alrex (Bausch & Lomb) |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a topical corticosteroid, loteprednol etabonate reduces inflammation, edema, and immune cell infiltration in ocular tissues. It is an ester-based corticosteroid designed to be metabolized more rapidly than other topical steroids, potentially reducing systemic absorption and adverse effects while maintaining local anti-inflammatory efficacy.
Approved indications
- Inflammation and pain following ocular surgery
- Seasonal allergic conjunctivitis
- Uveitis
- Dry eye disease
Common side effects
- Ocular irritation or discomfort
- Transient blurred vision
- Increased intraocular pressure
- Posterior subcapsular cataract formation (with prolonged use)
Key clinical trials
- Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (PHASE3)
- DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (PHASE4)
- Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model (PHASE4)
- Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium (PHASE4)
- Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis (PHASE4)
- Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol etabonate 0.2% CI brief — competitive landscape report
- Loteprednol etabonate 0.2% updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI